<DOC>
	<DOCNO>NCT00002233</DOCNO>
	<brief_summary>The purpose study see safe give combination four anti-HIV drug patient recently infect HIV never receive anti-HIV treatment . The effect combination drug immune system level HIV body study also . The four-drug combination include lamivudine , abacavir , amprenavir , indinavir .</brief_summary>
	<brief_title>A Study Combination Four Drugs Patients With Recent HIV Infection</brief_title>
	<detailed_description>Patients receive four-drug regimen consist two nucleoside reverse transcriptase inhibitor ( 3TC abacavir ) two protease inhibitor ( amprenavir indinavir ) minimum 48 week . At specified time point , patient undergo physical assessment efficacy evaluation include plasma HIV-1 RNA measurement CD4 cell count . Depending immunologic virologic status patient , test may do determine whether quadruple drug therapy attain undetectable viral level .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Amprenavir</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed caution and/or careful monitoring : Drugs may interact CYP3A4 ( e.g. , alprazolam , carbamazepine , codeine , clarithromycin , dapsone , diazepam , diltiazem , erythromycin , estrogens , fluvastatin , glucocorticoid , imipramine , lidocaine , lovastatin , nifedipine , phenobarbital , phenytoin , simvastatin , warfarin ) . Drugs inhibit cytosolic alcohol dehydrogenase ( e.g. , ethanol , disulfiram , chlorzoxazone , chlorpromazine , isoniazid , chloral hydrate ) . Drugs known affect renal tubular secretion ( e.g. , probenecid cimetidine ) , cause liver toxicity , induce myelosuppression . Patients must : Documented confirm acute HIV1 infection . No prior exposure antiretroviral treatment . Ability comply investigational nature study minimum 48 week . Consent parent guardian age 18 . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : A clinical diagnosis AIDS , exclude CD4+ cell count less 200/mm3 . A serious medical condition diabetes , congestive heart failure , cardiomyopathy , cardiac dysfunction , opinion investigator , compromise safety patient . Institutionalized mentally disabled . Inability comply dose schedule protocol evaluation reason specify . Concurrent Medication : Excluded : Concurrent therapy rifampin , rifabutin , terfenadine , astemizole , ketoconazole , itraconazole , cisapride , triazolam , midazolam , quinidine , amiodarone , and/or ergotamine/dihydroergotaminecontaining regimen . Foscarnet therapy agent document vitro vivo activity HIV1 . Medications known induce inhibit hepatic cytochrome P450 enzyme system . Vitamin E supplement . Concurrent Treatment : Excluded : Dependence blood transfusion . Other investigational treatment . Patients follow prior condition exclude : A history clinically relevant pancreatitis hepatitis within 6 month study entry . A history inflammatory bowel disease malignancy , intestinal ischemia , malabsorption , gastrointestinal dysfunction might interfere drug absorption render patient unable take oral medication . An unexplained fever 38.5 Celsius 14 day within 30 day study entry . A history coagulopathy . Prior Medication : Excluded : Prior exposure antiretroviral therapy . Therapy immunomodulating agent systemic corticosteroid , interleukin , thalidomide , anticytokine agent interferon , cytotoxic chemotherapeutic agent , antioxidant within 30 day study entry . Prior Treatment : Excluded : Radiation therapy within 30 day study entry . Risk Behavior : Excluded : Alcohol illicit drug use , opinion investigator , may interfere ability comply dose schedule protocol evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 1999</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>CD4 Lymphocyte Count</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
</DOC>